Nestlé Health Science, a subsidiary of food and nutrition product maker Nestlé, agreed yesterday to acquire UK-based medical device producer Phagenesis, allowing Nestlé-backed venture firm Inventages Venture Capital to exit.
The purchase price was not disclosed but a person familiar with the acquisition told the Wall Street Journal medical device companies of a similar size to Phagenesis ‘typically sell for £100m ($133m)’.
Founded in 2007, Phagenesis is the developer of a device called Phagenyx to treat dysphagia, a condition where…
